Gemcitabine and CT-011 for Resected Pancreatic Cancer

Clinical Trial ID NCT01313416

PubWeight™ 11.11^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01313416

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Prognostic indicators for survival after resection of pancreatic adenocarcinoma.	Am J Surg	1993	6.15
2	Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database.	J Am Coll Surg	1999	5.58
3	Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer.	Clin Cancer Res	2013	3.48
4	Intratumoral immunization: a new paradigm for cancer therapy.	Clin Cancer Res	2014	1.24
5	Review of adjuvant radiochemotherapy for resected pancreatic cancer and results from Mayo Clinic for the 5th JUCTS symposium.	Int J Radiat Oncol Biol Phys	2009	0.99
6	Cancer immunotherapy in clinical practice -- the past, present, and future.	Chin J Cancer	2014	0.98
7	Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies.	Drug Des Devel Ther	2015	0.97
8	Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future.	J Hematol Oncol	2015	0.91
9	IP-10/CXCL10 attracts regulatory T cells: Implication for pancreatic cancer.	Oncoimmunology	2015	0.87
10	Targeting CD8+ T-cell tolerance for cancer immunotherapy.	Immunotherapy	2014	0.81
11	Adjuvant treatment of pancreatic cancer in 2009: where are we? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.	JOP	2009	0.80
12	Specificity delivers: therapeutic role of tumor antigen-specific antibodies in pancreatic cancer.	Semin Oncol	2014	0.79
13	Immune checkpoint therapy for pancreatic cancer.	World J Gastroenterol	2016	0.79
14	Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer?	Oncoimmunology	2015	0.78